JP2003530124A - 新規幹細胞成長因子様ポリペプチドおよびポリヌクレオチドに関する方法および物質 - Google Patents

新規幹細胞成長因子様ポリペプチドおよびポリヌクレオチドに関する方法および物質

Info

Publication number
JP2003530124A
JP2003530124A JP2001575639A JP2001575639A JP2003530124A JP 2003530124 A JP2003530124 A JP 2003530124A JP 2001575639 A JP2001575639 A JP 2001575639A JP 2001575639 A JP2001575639 A JP 2001575639A JP 2003530124 A JP2003530124 A JP 2003530124A
Authority
JP
Japan
Prior art keywords
polypeptide
seq
polynucleotide
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001575639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003530124A5 (https=
Inventor
ワイ． タン，トム
ラバット，アイヴァン
ティー． ドルマナック，ラドジェ
マイズ，ナンシー
光郎 西川
カオ，チェン−チ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kirin Brewery Co Ltd
Original Assignee
Kirin Brewery Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery Co Ltd filed Critical Kirin Brewery Co Ltd
Publication of JP2003530124A publication Critical patent/JP2003530124A/ja
Publication of JP2003530124A5 publication Critical patent/JP2003530124A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2001575639A 2000-04-05 2001-04-05 新規幹細胞成長因子様ポリペプチドおよびポリヌクレオチドに関する方法および物質 Withdrawn JP2003530124A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US54377400A 2000-04-05 2000-04-05
US09/543,774 2000-04-05
US21573300P 2000-06-28 2000-06-28
US60/215,733 2000-06-28
US75756201A 2001-01-09 2001-01-09
US09/757,562 2001-01-09
US26661401P 2001-02-05 2001-02-05
US60/266,614 2001-02-05
PCT/US2001/011208 WO2001077169A2 (en) 2000-04-05 2001-04-05 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides

Publications (2)

Publication Number Publication Date
JP2003530124A true JP2003530124A (ja) 2003-10-14
JP2003530124A5 JP2003530124A5 (https=) 2008-06-19

Family

ID=27499020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001575639A Withdrawn JP2003530124A (ja) 2000-04-05 2001-04-05 新規幹細胞成長因子様ポリペプチドおよびポリヌクレオチドに関する方法および物質

Country Status (5)

Country Link
EP (1) EP1268543A2 (https=)
JP (1) JP2003530124A (https=)
AU (1) AU5904101A (https=)
CA (1) CA2405104A1 (https=)
WO (1) WO2001077169A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526248A (ja) * 2004-01-27 2007-09-13 ヌベロ インコーポレーティッド 胃腸増殖因子およびその使用方法
WO2008075796A1 (ja) * 2006-12-21 2008-06-26 Kyowa Hakko Kirin Co., Ltd. 血球回復促進剤
JP2015512389A (ja) * 2012-03-21 2015-04-27 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ヒトリンパ器官由来の抑制性ストローマ細胞の単離および使用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411052B2 (en) 2001-03-05 2008-08-12 Nuvelo, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
CA2462795A1 (en) * 2001-10-03 2003-04-10 Incyte Genomics, Inc. Secreted proteins
PL2157192T3 (pl) 2003-10-10 2014-01-31 Deutsches Krebsforsch Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)
US7541431B2 (en) 2005-09-07 2009-06-02 Maine Medical Center Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto
WO2007100357A2 (en) * 2005-10-07 2007-09-07 Nuvelo, Inc. Stem cell factor-like protein scfa1 and uses thereof
DK2066694T3 (en) 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
WO2008046649A1 (en) 2006-10-20 2008-04-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Rspondins as modulators of angiogenesis and vasculogenesis
EP2173379B2 (en) 2007-07-02 2023-07-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2393917B1 (en) 2009-02-03 2016-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells.
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
US20120039912A1 (en) 2009-04-15 2012-02-16 Galapagos Sasu Rspondin-3 inhibition in bone disorders
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
JP6185463B2 (ja) 2011-07-15 2017-08-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｒｓｐｏ結合剤およびその使用法
US9181333B2 (en) 2012-07-13 2015-11-10 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
CA2961374A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
GB201721615D0 (en) 2017-12-21 2018-02-07 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures
CN108607101A (zh) * 2018-05-04 2018-10-02 广西中医药大学附属瑞康医院 Zip1基因在制备抑制骨髓间充质干细胞凋亡的产品中的应用
CN111420034A (zh) * 2019-01-08 2020-07-17 上海莱馥医疗科技有限公司 一种用于治疗银屑病的混合干细胞制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7159898A (en) * 1997-04-25 1998-11-24 Genetics Institute Inc. Secreted proteins and polynucleotides encoding them
CA2365247A1 (en) * 1999-03-19 2000-09-28 Human Genome Sciences, Inc. 49 human secreted proteins
CN1297930A (zh) * 1999-11-29 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人凝血栓蛋白30和编码这种多肽的多核苷酸
CA2399776A1 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526248A (ja) * 2004-01-27 2007-09-13 ヌベロ インコーポレーティッド 胃腸増殖因子およびその使用方法
US7951381B2 (en) 2004-01-27 2011-05-31 Kyowa Hakko Kirin Co., Ltd. Method of stimulating epithelial cell proliferation by administration of gastrointestinal proliferative factor
WO2008075796A1 (ja) * 2006-12-21 2008-06-26 Kyowa Hakko Kirin Co., Ltd. 血球回復促進剤
JP2015512389A (ja) * 2012-03-21 2015-04-27 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ヒトリンパ器官由来の抑制性ストローマ細胞の単離および使用
US10420801B2 (en) 2012-03-21 2019-09-24 The General Hospital Corporation Isolation and use of human lymphoid organ-derived suppressive stromal cells

Also Published As

Publication number Publication date
CA2405104A1 (en) 2001-10-18
WO2001077169A3 (en) 2002-07-04
WO2001077169A9 (en) 2002-12-19
EP1268543A2 (en) 2003-01-02
AU5904101A (en) 2001-10-23
WO2001077169A2 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
US7319141B2 (en) Stem cell growth factor-like polypeptides
JP4284375B2 (ja) 幹細胞増殖因子様ポリペプチドおよびポリヌクレオチドに関する方法および材料
JP2003530124A (ja) 新規幹細胞成長因子様ポリペプチドおよびポリヌクレオチドに関する方法および物質
WO2002022815A1 (en) Methods and materials relating to neuropilin-like polypeptides and polynucleotides
JP2006517094A (ja) 新規核酸およびポリペプチド
US6673904B2 (en) Stem cell growth factor-like polypeptides
US20050192215A1 (en) Methods and materials relating to novel polypeptides and polynucleotides
JP2003521903A (ja) Ｃｄ８４様ポリペプチドおよびポリヌクレオチドに関する方法と材料
US7067301B2 (en) Methods and materials relating to novel prothrombinase-like polypeptides and polynucleotides
JP2004502403A (ja) アルファ−２−マクログロブリン様ポリペプチドおよびポリヌクレオチドに関する方法と材料
US7317099B2 (en) Polynucleotides encoding stem cell growth factor-like polypeptides
JP2004502405A (ja) トランスフォ−ミング成長因子アルファｔｇｆアルファ様ポリペプチドおよびポリヌクレオチドに関する方法と材料
US7109030B2 (en) Methods of therapy and diagnosis using insulin-like growth factor binding protein-like polypeptides and polynucleotides
US20070141566A1 (en) Methods and materials relating to novel polypeptides and polynucleotides
US20030138804A1 (en) Methods and materials relating to novel C-type lectin receptor-like polypeptides and polynucleotides
JP2004500120A (ja) インスリン様増殖因子結合タンパク質様ポリペプチドおよびポリヌクレオチドに関する方法と材料
JP2004524001A (ja) 白血球免疫グロブリン受容体（ｌｉｒ様）ポリペプチドおよびポリヌクレオチドに関する方法と材料
JP2004500081A (ja) ロイシン・リッチ反復蛋白質様（ｌｒｒ蛋白質様）ポリペプチドおよびポリヌクレオチドに関する方法と材料
JP2004500078A (ja) 癌胎児抗原様（ｃｅａ様）ポリペプチドおよびポリヌクレオチドに関する方法と材料
JP2004515207A (ja) メタロカルボキシペプチダーゼ様ポリペプチドおよびポリヌクレオチドに関する方法と材料
US20050153334A1 (en) Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides
JP2003521928A (ja) 前含脂肪細胞因子−１様（Ｐｒｅｆ−１様）ポリペプチドおよびポリヌクレオチドに関する方法と材料
JP2003521251A (ja) Ｃｕｂドメイン・ポリペプチドおよびポリヌクレオチドに関する方法と材料
US20040162419A1 (en) Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides
US20060074044A1 (en) Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071015

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20071015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071015

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20081015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081120

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090525